Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Moses

Showing results (371-380 of 400) with videos related to

Pageof 40
Sort By:
Scientific Reports|July 15, 2018
Sustainable Syntheses of (-)-Jerantinines A & E and Structural Characterisation of the Jerantinine-Tubulin Complex at the Colchicine Binding SiteChristopher J Smedley, Paul A Stanley, Mohannad E Qazzaz, et al.
Cancer Care Research Online|April 8, 2024
A Preliminary Validation of an Optimal Cutpoint in Total Number of Patient-Reported Symptoms in Head and Neck Cancer for Effective Alignment of Clinical Resources with Patients' Symptom BurdenJanet H Van Cleave, Catherine Concert, Maria Kamberi, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Autoimmunity|June 8, 2019
The proteasome activator REGγ counteracts immunoproteasome expression and autoimmunityLiangfang Yao, Lei Zhou, Yang Xuan, et al.
Nature Communications|August 12, 2021
Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulationXiaohong Tan, Lu Tong, Lin Li, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Nature Communications|April 16, 2021
Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductaseSimon Bo Jensen, Sara Thodberg, Shaheena Parween, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2019
Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics CombinationRan Nir-Paz, Daniel Gelman, Ayman Khouri, et al.
Nature Communications|June 15, 2026
Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faeciumKyong T Fam, Pavan Kumar Chodisetti, Zifei Wang, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant <i>Enterococcus faecium</i>Kyong T Fam, Pavan Kumar Chodisetti, Zifei Wang, et al.
Pageof 40

Showing results (371-380 of 400) with videos related to

Sort By:
Pageof 40
Scientific Reports|July 15, 2018
Sustainable Syntheses of (-)-Jerantinines A & E and Structural Characterisation of the Jerantinine-Tubulin Complex at the Colchicine Binding SiteChristopher J Smedley, Paul A Stanley, Mohannad E Qazzaz, et al.
Cancer Care Research Online|April 8, 2024
A Preliminary Validation of an Optimal Cutpoint in Total Number of Patient-Reported Symptoms in Head and Neck Cancer for Effective Alignment of Clinical Resources with Patients' Symptom BurdenJanet H Van Cleave, Catherine Concert, Maria Kamberi, et al.
Inflammatory Bowel Diseases|October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Journal of Autoimmunity|June 8, 2019
The proteasome activator REGγ counteracts immunoproteasome expression and autoimmunityLiangfang Yao, Lei Zhou, Yang Xuan, et al.
Nature Communications|August 12, 2021
Loss of Smad4 promotes aggressive lung cancer metastasis by de-repression of PAK3 via miRNA regulationXiaohong Tan, Lu Tong, Lin Li, et al.
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Nature Communications|April 16, 2021
Biased cytochrome P450-mediated metabolism via small-molecule ligands binding P450 oxidoreductaseSimon Bo Jensen, Sara Thodberg, Shaheena Parween, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 15, 2019
Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics CombinationRan Nir-Paz, Daniel Gelman, Ayman Khouri, et al.
Nature Communications|June 15, 2026
Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant Enterococcus faeciumKyong T Fam, Pavan Kumar Chodisetti, Zifei Wang, et al.
Biorxiv : the Preprint Server for Biology|March 27, 2026
Genetic and pharmacological inactivation of peptidoglycan remodeling increases antibiotic susceptibility of vancomycin-resistant <i>Enterococcus faecium</i>Kyong T Fam, Pavan Kumar Chodisetti, Zifei Wang, et al.
Pageof 40